Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
Novo Nordisk NVO announced that it has submitted a regulatory filing seeking label expansion for a higher dose of its blockbuster obesity drug, Wegovy (injectable semaglutide). The FDA filing seeks approval for a 7.2 mg dose of the drug, which Novo Nordisk claims provides an option for “greater weight loss potential” than what is currently being […]
Get the Government Out of the GLP-1 Market
Its involvement often leads to distortions and perverse incentives. Dr. Gilberto de Lima Lopes Jr. is right that the market for medications is imperfect, but it is often government that is the culprit (“ The Free Market Alone Won’t Cut GLP-1 Prices,” Letters, Nov. 21). Oncology, his speciality, is the …
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct therapeutic areas. NVO is widely recognized as the market leader in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic (pre-filled pen) and Rybelsus (oral tablet) for type II diabetes (T2D), […]
Diagnostics, Vol. 15, Pages 3025: Beyond BMI: Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine
Diagnostics, Vol. 15, Pages 3025: Beyond BMI: Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine Diagnostics doi: 10.3390/diagnostics15233025 Authors: Maria-Daniela Tanasescu Andrei-Mihnea Rosu Alexandru Minca Andreea-Liana Rosu Maria-Mihaela Grigorie Delia Timofte Dorin Ionescu Obesity remains a dominant risk factor for cardiovascular disease, yet its classification continues to rely heavily on body […]
JCM, Vol. 14, Pages 8413: Epicardial Fat and Heart Failure in Type 2 Diabetes: Metabolism, Imaging and Novel Biomarkers—A Translational Perspective
JCM, Vol. 14, Pages 8413: Epicardial Fat and Heart Failure in Type 2 Diabetes: Metabolism, Imaging and Novel Biomarkers—A Translational Perspective Journal of Clinical Medicine doi: 10.3390/jcm14238413 Authors: Pedro Gil-Millan José Rives José Luis Sánchez-Quesada Antonio Pérez Heart failure (HF) is a major cardiovascular complication in people with type 2 diabetes (T2D), where heart failure […]
Thanksgiving foods to skip while taking ozempic or other weight-loss drugs, says dietitian
For individuals taking GLP‑1 medications such as Ozempic, Thanksgiving doesn’t have to be restrictive, but specific foods and beverages need caution. Dietitian Kylie Bensley recommends avoiding mac and cheese, candied yams, and heavy or cream-based alcoholic drinks because of their impact on blood sugar and digestion. Safer choices are protein packed foods, vegetables, light desserts […]
GLP-1 drugs may be associated with an increased risk of chronic cough, raising the need to study this mechanism and longitudinal cough dynamics objectively
submitted by /u/Cough_Geek [link] [comments]
Are Sexual Side Effects Emerging With GLP-1 Agonists?
GLP-1 receptor agonists affect sexual function differently across individuals and influencing libido and hormone levels in men and women during treatment. Medscape News Europe
Is Chronic Cough Another Side Effect of GLP-1 Drugs?
(MedPage Today) — GLP-1 receptor agonist use was associated with chronic cough regardless of a previous gastroesophageal reflux disease (GERD) diagnosis, a study of over 2 million people with type 2 diabetes suggested. Adults prescribed a GLP…
15 high-cost drugs, including Ozempic, get major Medicare price reductions in latest negotiation round
A wave of vital prescription drugs is about to get a lot cheaper for people on Medicare. The Trump administration announced Tuesday that it has successfully negotiated lower prices for 15 drugs, including medications used for asthma, diabetes, arthritis and multiple forms of cancer. The list includes Ozempic and Wegovy, Novo Nordisk’s drugs for Type […]